Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Glaukos price target raised to $60 from $50 at Piper Sandler » 04:54
08/07/20
08/07
04:54
08/07/20
04:54
GKOS

Glaukos

$49.08 /

-1.13 (-2.25%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Glaukos to $60 from $50 and reiterates an Overweight rating on the shares. The company's Q2 results handily beat expectations as both of its U.S. businesses recovered nicely since the April lows to greater than 80% of pre-COVID levels, and management noted these trends have continued into July, O'Brien tells investors in a research note. Management did portray a "careful tone" noting that future virus spread could dampen patient willingness to return for procedures or receive diagnoses, but the long-term reopening trend remains positive and this commentary "will likely prove overly cautious," says the analyst.

ShowHide Related Items >><<
GKOS Glaukos
$49.08 /

-1.13 (-2.25%)

GKOS Glaukos
$49.08 /

-1.13 (-2.25%)

08/05/20 Piper Sandler
Proposed CMS rates positive for Glaukos, says Piper Sandler
06/15/20 Jefferies
Glaukos initiated with a Hold at Jefferies
05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
GKOS Glaukos
$49.08 /

-1.13 (-2.25%)

GKOS Glaukos
$49.08 /

-1.13 (-2.25%)

Earnings
Glaukos can't predict impact of the COVID-19 on results » 16:20
08/06/20
08/06
16:20
08/06/20
16:20
GKOS

Glaukos

$49.09 /

-1.12 (-2.23%)

The company said,…

The company said, "As previously announced in a press release issued on March 24, 2020, due to the rapidly evolving environment and continued uncertainties from the impact of COVID-19, Glaukos has withdrawn its previously announced annual guidance for 2020, which was issued on February 27, 2020. At this date, Glaukos cannot predict the specific extent, or duration, of the impact of the COVID-19 outbreak on its financial and operating results."

ShowHide Related Items >><<
GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

08/05/20 Piper Sandler
Proposed CMS rates positive for Glaukos, says Piper Sandler
06/15/20 Jefferies
Glaukos initiated with a Hold at Jefferies
05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

Earnings
Glaukos reports Q2 EPS (61c), consensus (76c) » 16:19
08/06/20
08/06
16:19
08/06/20
16:19
GKOS

Glaukos

$49.09 /

-1.12 (-2.23%)

Reports Q2 revenue…

Reports Q2 revenue $31.6M, consensus $20.06M. The company's CEO said, "We are encouraged with the initial return of elective procedures around the world and remain well-positioned to provide our essential ophthalmic therapies to our customers and their patients during the ongoing recovery period. I am confident the longer-term fundamental prospects of our business remain strong as we advance our mission to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs."

ShowHide Related Items >><<
GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

08/05/20 Piper Sandler
Proposed CMS rates positive for Glaukos, says Piper Sandler
06/15/20 Jefferies
Glaukos initiated with a Hold at Jefferies
05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

GKOS Glaukos
$49.09 /

-1.12 (-2.23%)

Recommendations
Proposed CMS rates positive for Glaukos, says Piper Sandler » 04:58
08/05/20
08/05
04:58
08/05/20
04:58
GKOS

Glaukos

$47.22 /

+0.22 (+0.47%)

The Centers for Medicare…

The Centers for Medicare and Medicaid Services yesterday issued its proposed rule for 2021 for Medicare facility reimbursement in the ambulatory surgery center and hospital outpatient department settings, Piper Sandler analyst Matt O'Brien tells investors in a research note. The analyst views the changes positively for Glaukos, saying that if finalized, the company's iStent reimbursement rate would raise a "healthy couple percentage points" in both settings. He keeps an Overweight rating on the shares with a $50 price target.

ShowHide Related Items >><<
GKOS Glaukos
$47.22 /

+0.22 (+0.47%)

GKOS Glaukos
$47.22 /

+0.22 (+0.47%)

06/15/20 Jefferies
Glaukos initiated with a Hold at Jefferies
05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
GKOS Glaukos
$47.22 /

+0.22 (+0.47%)

GKOS Glaukos
$47.22 /

+0.22 (+0.47%)

Over a month ago
Initiation
Glaukos initiated with a Hold at Jefferies » 06:33
06/15/20
06/15
06:33
06/15/20
06:33
GKOS

Glaukos

$38.63 /

+0.98 (+2.60%)

Jefferies analyst Anthony…

Jefferies analyst Anthony Petrone initiated coverage of Glaukos with a Hold rating and $44 price target. The company's "deep portfolio" of current and emerging solutions position it to potentially emerge as a lead vision care player, but he starts the stock with a Hold rating to account for uncertainties around near-term MIGS share shift, COVID-19 headwinds, and Glaukos' upcoming Ivantis patent suit, Petrone tells investors.

ShowHide Related Items >><<
GKOS Glaukos
$38.63 /

+0.98 (+2.60%)

GKOS Glaukos
$38.63 /

+0.98 (+2.60%)

05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
GKOS Glaukos
$38.63 /

+0.98 (+2.60%)

GKOS Glaukos
$38.63 /

+0.98 (+2.60%)

Syndicate
Glaukos reports proposed private offering of $200M convertible senior notes » 09:13
06/08/20
06/08
09:13
06/08/20
09:13
GKOS

Glaukos

$46.81 /

+4.21 (+9.88%)

Glaukos Corporation…

Glaukos Corporation announced that it intends to offer, subject to market and other conditions, $200M aggregate principal amount of Convertible Senior Notes due 2027 in a private offering. The notes will be offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended. Glaukos expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $30M aggregate principal amount of the notes. Glaukos intends to use the net proceeds from the offering to pay the cost of the capped call transactions described below and the remainder for working capital and general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, Glaukos expects to use a portion of the related net proceeds to enter into additional capped call transactions and any remainder for working capital and general corporate purposes.

ShowHide Related Items >><<
GKOS Glaukos
$46.81 /

+4.21 (+9.88%)

GKOS Glaukos
$46.81 /

+4.21 (+9.88%)

05/08/20 Piper Sandler
Glaukos price target lowered to $50 from $62 at Piper Sandler
05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
GKOS Glaukos
$46.81 /

+4.21 (+9.88%)

GKOS Glaukos
$46.81 /

+4.21 (+9.88%)

Over a quarter ago
Recommendations
Glaukos price target lowered to $50 from $62 at Piper Sandler » 05:20
05/08/20
05/08
05:20
05/08/20
05:20
GKOS

Glaukos

$41.20 /

+0.4 (+0.98%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Glaukos to $50 from $62 and keeps an Overweight rating on the shares following the company's Q1 results. Not surprisingly, COVID-19 weighed heavily on the company's results in Q1, O'Brien tells investors in a research note. While the near-term outlook is challenged, Glaukos has the pipeline and expertise to become a larger force in ophthalmology, says the anlayst.

ShowHide Related Items >><<
GKOS Glaukos
$41.20 /

+0.4 (+0.98%)

05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
03/24/20 Piper Sandler
Glaukos longer-term fundamentals fully intact, says Piper Sandler
Earnings
Glaukos reports Q1 adjusted EPS (44c), consensus (39c) » 16:16
05/07/20
05/07
16:16
05/07/20
16:16
GKOS

Glaukos

$41.20 /

+0.4 (+0.98%)

Reports Q1 revenue…

Reports Q1 revenue $55.3M, consensus $59.14M. "I want to recognize the dedication and resiliency of our employees who continue to move our company forward despite unique challenges associated with the COVID-19 pandemic. I also want to express our deep gratitude for the healthcare workers and first responders who are selflessly serving on the frontlines to take care of those in need," said Thomas Burns, Glaukos president and chief executive officer. "In response to COVID-19, Glaukos immediately reviewed and implemented numerous measures to prioritize the health and safety of our employees and their families, support our customers, preserve jobs globally, protect core research and development programs and maintain our strong financial and operating position following the COVID-19 pandemic. While our near-term business trends have been and continue to be materially impacted due to the shift of healthcare systems resources to the treatment of COVID-19 and government restrictions on elective procedures, I am confident the longer-term fundamental prospects of our business remain strong as we advance our mission to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs. We remain well-positioned to provide our essential ophthalmic therapies to customers and their patients as deferred procedures ultimately return in the future as the COVID-19 pandemic subsides."

ShowHide Related Items >><<
GKOS Glaukos
$41.20 /

+0.4 (+0.98%)

05/06/20 Wells Fargo
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight
04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
03/24/20 Piper Sandler
Glaukos longer-term fundamentals fully intact, says Piper Sandler
Recommendations
Wells Fargo says it appears Glaukos won some tentative rulings in patent fight » 10:18
05/06/20
05/06
10:18
05/06/20
10:18
GKOS

Glaukos

$43.20 /

+4.68 (+12.15%)

Wells Fargo analyst…

Wells Fargo analyst Lawrence Biegelsen said the court presiding over Glaukos' suit against Ivantis for patent infringement apparently posted a tentative ruling on some of the pending motions on Friday, according to the firm's patent consultant. However, "instead of posting it electronically, the Court literally taped it to the door, physically, so the companies have the rulings, but he does not, Biegelsen tells investors. It looks like the court tentatively ruled that Glaukos' full patent can be enforced through 2025, not just the small number of claims that literally cover Glaukos' original stent, but the court "might yet change its mind according to our patent consultant," Biegelsen said. While he doesn't have enough information to report anything definitive yet, it seems likely that Glaukos won several issues in the tentative ruling, added the analyst, who has an Underweight rating on Glaukos shares.

ShowHide Related Items >><<
GKOS Glaukos
$43.20 /

+4.68 (+12.15%)

04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
03/24/20 Piper Sandler
Glaukos longer-term fundamentals fully intact, says Piper Sandler
03/04/20 Citi
Glaukos initiated with a Sell at Citi
Conference/Events
Stephens analysts hold an analyst/industry conference call » 12:55
04/16/20
04/16
12:55
04/16/20
12:55
ABMD

Abiomed

$159.25 /

-0.37 (-0.23%)

, ALC

Alcon

$50.51 /

-0.22 (-0.43%)

, AVNS

Avanos

$28.42 /

-0.32 (-1.11%)

, BSX

Boston Scientific

$35.08 /

+0.255 (+0.73%)

, ESTA

Establishment Labs

$14.09 /

+0.18 (+1.29%)

, GKOS

Glaukos

$33.72 /

+0.255 (+0.76%)

, SIEN

Sientra

$1.75 /

+ (+0.00%)

, STE

Steris

$151.40 /

-3.31 (-2.14%)

, STAA

Staar Surgical

$35.75 /

-0.29 (-0.80%)

, TFX

Teleflex

$327.84 /

-2.73 (-0.83%)

, EHC

Encompass Health

$68.94 /

-0.82 (-1.18%)

, HCA

HCA Healthcare

$108.25 /

-1.28 (-1.17%)

, THC

Tenet

$18.84 /

-0.68 (-3.48%)

, UNH

UnitedHealth

$290.00 /

+8.23 (+2.92%)

, UHS

Universal Health

$100.27 /

-2.72 (-2.64%)

Analysts, along with…

Analysts, along with Darin Hill, CEO of Compass Surgical Partners, hold an Analyst/Industry conference call on April 16 at 1:30 pm.

ShowHide Related Items >><<
ABMD Abiomed
$159.25 /

-0.37 (-0.23%)

03/23/20 Piper Sandler
Abiomed's Impella may play role in treating COVID-19, says Piper Sandler
02/12/20
Fly Intel: Top five analyst downgrades
02/12/20 Morgan Stanley
Abiomed downgraded to Underweight on Impella pressures at Morgan Stanley
02/12/20 Piper Sandler
Abiomed risk/reward attractive for longer term investors, says Piper Sandler
ALC Alcon
$50.51 /

-0.22 (-0.43%)

04/09/20 Wells Fargo
Alcon price target lowered to $58 from $70 at Wells Fargo
04/08/20 Baird
Alcon downgraded to Neutral at Baird
04/08/20 Baird
Alcon downgraded to Neutral from Outperform at Baird
03/26/20 Argus
Alcon upgraded to Buy from Hold at Argus
AVNS Avanos
$28.42 /

-0.32 (-1.11%)

04/13/20 Barclays
Avanos upgraded to Equal Weight from Underweight at Barclays
12/30/19 Stifel
Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
11/06/19 Stifel
Avanos downgraded to Hold from Buy at Stifel
BSX Boston Scientific
$35.08 /

+0.255 (+0.73%)

04/09/20 Raymond James
Boston Scientific price target lowered to $42 from $49 at Raymond James
04/02/20 Piper Sandler
Piper reiterates Overweight rating on Boston Scientific, sees bounce back coming
04/01/20 Goldman Sachs
Boston Scientific upgraded to Conviction Buy from Neutral at Goldman Sachs
03/30/20 Piper Sandler
Boston Scientific will bounce back well post COVID-19, says Piper Sandler
ESTA Establishment Labs
$14.09 /

+0.18 (+1.29%)

01/03/20 BTIG
Zimmer Biomet, Staar Surgical, ViewRay among top 2020 picks at BTIG
07/24/19 Wells Fargo
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
07/12/19 Wells Fargo
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
07/11/19 Wells Fargo
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
GKOS Glaukos
$33.72 /

+0.255 (+0.76%)

04/09/20 Piper Sandler
Glaukos longer term fundamentals 'fully intact,' says Piper Sandler
04/08/20 Wells Fargo
Glaukos price target lowered to $34 from $53 at Wells Fargo
03/24/20 Piper Sandler
Glaukos longer-term fundamentals fully intact, says Piper Sandler
03/04/20 Citi
Glaukos initiated with a Sell at Citi
SIEN Sientra
$1.75 /

+ (+0.00%)

03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
03/12/20 SVB Leerink
Sientra price target lowered to $6.50 from $13 at SVB Leerink
03/12/20 Maxim
Sientra price target lowered to $8 from $12 at Maxim
03/12/20 Canaccord
Sientra price target lowered to $9 from $13 at Canaccord
STE Steris
$151.40 /

-3.31 (-2.14%)

07/10/19 KeyBanc
Steris downgraded to Sector Weight on valuation at KeyBanc
07/09/19 KeyBanc
STERIS downgraded to Sector Weight from Overweight at KeyBanc
05/15/19 Stephens
STERIS price target raised to $150 from $135 at Stephens
STAA Staar Surgical
$35.75 /

-0.29 (-0.80%)

03/04/20
BTIG healthcare analysts to hold an analyst/industry conference call
01/31/20 Benchmark
Too early to call China emergency impact on Staar Surgical, says Benchmark
01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
TFX Teleflex
$327.84 /

-2.73 (-0.83%)

04/03/20 Raymond James
Teleflex price target lowered to $360 from $450 at Raymond James
02/20/20 Piper Sandler
Teleflex price target raised to $425 from $400 at Piper Sandler
12/12/19 Wells Fargo
SeaSpine, Glaukos double-downgraded to Underweight at Wells Fargo
10/31/19 Piper Sandler
Urolift driving majority of Teleflex earnings beat, says Piper Jaffray
EHC Encompass Health
$68.94 /

-0.82 (-1.18%)

03/06/20 Deutsche Bank
Encompass Health price target raised to $83 from $73 at Deutsche Bank
03/05/20 BMO Capital
Encompass Health price target raised to $95 from $88 at BMO Capital
03/05/20 Baird
Encompass Health price target raised to $100 from $85 at Baird
03/05/20 Stephens
Encompass Health price target raised to $100 from $91 at Stephens
HCA HCA Healthcare
$108.25 /

-1.28 (-1.17%)

03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
02/03/20 Barclays
HCA Healthcare price target raised to $177 from $172 at Barclays
01/29/20 Truist
HCA Healthcare price target raised to $185 from $175 at SunTrust
01/29/20 Oppenheimer
HCA Healthcare price target raised to $160 from $155 at Oppenheimer
THC Tenet
$18.84 /

-0.68 (-3.48%)

04/03/20 Truist
Tenet price target lowered to $18 from $42 at SunTrust
03/11/20 RBC Capital
Tenet upgraded to Outperform from Sector Perform at RBC Capital
02/26/20
Fly Intel: Top five analyst upgrades
UNH UnitedHealth
$290.00 /

+8.23 (+2.92%)

04/16/20 Raymond James
UnitedHealth price target lowered to $325 from $340 at Raymond James
04/16/20 Credit Suisse
UnitedHealth price target lowered to $325 from $330 at Credit Suisse
04/16/20 Cowen
UnitedHealth price target lowered to $320 from $340 at Cowen
04/09/20 Cleveland Research
UnitedHealth existing 2020 guidance looks achievable, says Cleveland Research
UHS Universal Health
$100.27 /

-2.72 (-2.64%)

03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
03/23/20 BofA
Universal Health downgraded to Neutral from Buy at BofA
01/07/20 BofA
Universal Health named top 2020 Health Care Facilities pick at BofA

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.